Antiepileptic — Multiple Mechanisms
Pregnancy: Avoid — teratogenic in animals; use effective contraception
Zonisamide
Brand names: Zonegran
Adult dose
Dose: 100 mg once daily initially; increase by 100 mg every 2 weeks; maintenance 300–500 mg/day
Route: Oral
Frequency: Once or twice daily
Max: 500 mg/day
Broad-spectrum AED — blocks Na+ and T-type Ca2+ channels, inhibits carbonic anhydrase. Adjunctive treatment for focal seizures. Also studied in Parkinson's disease (off-label). Long half-life (63 hours) allows once-daily dosing.
Paediatric dose
Dose: 1 mg/day/kg
Route: Oral
Frequency: Once daily
Max: 12 mg/kg/day (max 500 mg/day)
Children ≥6 years: 1 mg/kg/day increasing to 6–8 mg/kg/day.
Dose adjustments
Renal
Caution — avoid if eGFR <50 mL/min (insufficient data). Withdraw gradually.
Hepatic
Caution in hepatic impairment — slower titration required.
Paediatric weight-based calculator
Children ≥6 years: 1 mg/kg/day increasing to 6–8 mg/kg/day.
Clinical pearls
- Renal stones: adequate hydration (>2L/day) is mandatory — carbonic anhydrase inhibition raises urinary pH, promoting stone formation
- Oligohydrosis and hyperthermia: particularly in children — counsel caregivers to monitor for reduced sweating and fever. Withdraw drug and seek medical attention.
- Weight loss effect sometimes exploited therapeutically in overweight patients with epilepsy
Contraindications
- Sulfonamide hypersensitivity (zonisamide is a sulfonamide derivative)
- Severe hepatic impairment
Side effects
- Anorexia and weight loss
- Renal stones (carbonic anhydrase inhibition — hydration essential)
- Cognitive impairment
- Metabolic acidosis
- Oligohydrosis and hyperthermia (especially in children)
- Depression and suicidal ideation
Interactions
- CYP3A4 inducers — carbamazepine/phenytoin (reduce zonisamide levels)
- CYP3A4 inhibitors — fluconazole (increase levels)
- Carbonic anhydrase inhibitors — topiramate (additive stone risk and metabolic acidosis)
Monitoring
- Serum bicarbonate (metabolic acidosis)
- Renal function and urine for haematuria (stones)
- Weight
- Cognitive function assessment
Reference: BNFc; BNF 90; NICE NG217; BNFc; EMA Zonegran SPC. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Multiple Organ Dysfunction Score (MODS) · Organ Failure Assessment
- International Staging System (ISS) for Multiple Myeloma · Multiple Myeloma
- Revised ISS (R-ISS) for Multiple Myeloma · Haematological Malignancy
- SLiM-CRAB Criteria for Multiple Myeloma · Myeloma
- Multiple Myeloma Response Criteria (IMWG 2016) · Myeloma
- IMPEDE-VTE Score for VTE Risk in Multiple Myeloma · Myeloma
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS